Berlex Fellowship Open

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

DUMONT, NJ--The Berlex Oncology Foundation is accepting applications until January 6, 1997, for a 2-year clinical research training program open to academically oriented physicians specializing in oncology. The intent is to encourage careers in clinical cancer research. For more information, contact Svetlana Lisanti, Berlex Oncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; or call 201-385-0006.

DUMONT, NJ--The Berlex Oncology Foundation is accepting applicationsuntil January 6, 1997, for a 2-year clinical research trainingprogram open to academically oriented physicians specializingin oncology. The intent is to encourage careers in clinical cancerresearch. For more information, contact Svetlana Lisanti, BerlexOncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; orcall 201-385-0006.

Articles in this issue
Routine Office Endometrial Biopsies and Ultrasound Screening Are Not Recommended for Breast Cancer Patients Receiving Tamoxifen
AHCPR to Fund Analysis of the Impact of Managed Care's Growth
Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women
ASTRO Honors Two Members With Gold Medal and Bestows Honorary Memberships on Two
Friends of Cancer Research Campaign
Four Cancer Chemoprevention Trials Seek Subjects
Overall US Cancer Mortality Rate Falls for the First Time
Four Scenarios Describe Impact of Cancer Research in 2015
New Edition of NABCO Breast Cancer Resource List Is Now Available
Changes in Congressional Committee Chairmen Could Impact Oncologists
Growth Factor in Elderly ALL Patients Improves Outcome
Human Genetic Map Goes On-Line
Study to Explore Smoking Cessation After a Cancer Diagnosis
Novantrone Gets FDA Nod for Use in Advanced Prostate Cancer
New Cancer Programs, Office of Cancer Survivorship Announced
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
5 experts in this video
5 experts in this video
Related Content
Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC

Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC

Ariana Pelosci
March 13th 2025
Article

The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting

Russ Conroy
March 13th 2025
Article

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

ONCOLOGY Staff
March 13th 2025
Article

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases

Russ Conroy
March 12th 2025
Article

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.